Can Novavax's Coronavirus Vaccine Be Valued?

Can Novavax's Coronavirus Vaccine Be Valued?

Source: 
Motley Fool
snippet: 

It doesn't surprise me that a small-cap biotech company like Novavax (NASDAQ:NVAX) skyrocketed when the COVID-19 pandemic began. Millions of people will need to be vaccinated against the virus this year and next. The market opportunity is at once vast and risky (as biotech investing often is). Even after the vaccine candidate completes clinical trials, there is always a chance the U.S. Food and Drug Administration (FDA) will reject Novavax's vaccine application.